Vasculotropin (VAS) is a recently identified growth factor angiogenic in vitro as well as in vivo. 1 It is also referred to as vascular endothelial growth factor (VEGF) 2 or vascular permeability factor (VPF). 3 The human gene of this angiogenic factor has been cloned and sequenced. 4 ' 5 The encoded protein displays a structural homology with the A and B chains of platelet-derived growth factor (PDGF). By alternative splicing of the same mRNA, three molecular species are generated corresponding to amino acids 121,165, and 189. 6 A fourth form is generated by inserting 51 bases on an acceptor site and corresponds to a 206 amino acid peptide. 7 Unlike other angiogenic molecules, such as basic and acidic fibroblast growth factors October 19, 1993; revised December 27, 1993 ; accepted March 3, 1994 (bFGF and aFGF) or platelet-derived endothelial growth factor (PD-ECGF) that lack a signal sequence, VAS-VEGF contains a signal sequence, and all four forms are expected to be secreted. However, if the 121 and 165 forms are freely soluble in the medium, the 189 and 206 forms remain cell associated. 7 So far, VAS-VEGF has been reported to act through a paracrine pathway on vascular endothelial cells 8 ' 9 or on IL2-stimulated human lymphocytes. 10 It has also been shown to be angiogenic in the chorioallantoic membrane of the chicken embryo 1 and the rabbit cornea" and is able to induce increased blood vessel permeability in the Miles assay. 3 Because angiogenesis and vascular permeability are two crucial steps leading to the onset of several vascular retinal diseases such as diabetic proliferative retinopathy, we investigated the possible implication of VAS-VEGF in retinal physiology and vascular diseases.
METHODS

Preparation of Growth Factors and Antibodies
Human recombinant VAS-VEGF 165 was expressed in a baculovirus expression system as described by Co- hen et al. 12 Human recombinant bFGF was expressed in Escherichia coli and was a generous gift from H. Prats (INSERM, Toulouse, France).
A monospecific anti-VAS-VEGF antibody was raised in chickens cared for in accordance with the ARVO Resolution on Use of Animals in Research. To obtain purified anti-VAS-VEGF-specific antibodies, an affinity column was prepared by coupling 1 mg of human recombinant VAS-VEGF to 1 ml of CNBractivated Sepharose 4 B (Pharmacia, Uppsala, Sweden). The specific antibodies were eluted using glycine HC1 0.2 M pH 2.5 and immediately buffered with Tris HC1 pH 8. The presence of antibodies to VAS-VEGF in the nonretained fraction and the purified antibodies was tested by an ELISA assay and Western blot analysis. Furthermore, these specific antibodies did not cross-react with other angiogenic growth factors such as aFGF, bFGF, PDGF BB, or TGB /?.
Cell Culture Conditions
Bovine retinal endothelial cells (BRECs) were isolated and cultured from bovine retinal capillaries as previously described. 13 Briefly, BRECs were cultured on gelatin-coated dishes in Dulbecco's modified Eagle medium (DMEM) supplemented with 10% calf serum, at 37°C in a humidified atmosphere containing 10% CO 2 . For all experiments, cells were used at pass numbers between 4 and 8. The endothelial origin was ascertained by Von Willebrand immunocytochemistry as previously described.
14 Fetal bovine aortic endothelial cells (FBAEs) were cultured according to Gospodarowicz et al. 15 Conditioned media (BREC-CM and FBAE-CM) were obtained by replacing the medium of confluent cells by serum-free DMEM in the presence of insulin (5 /ig/ml) and transferrin (10 fig/ml ). Conditioned media were collected 48 hours later, centrifuged, and stored at -20°C until used.
Binding Assays VAS-VEGF 165 was iodinated using chloramine-T reagent as previously described 16 and stored at -80°C until used.
Subconfluent cells in 12 multiwell plates were transferred at 4°C, washed twice with binding buffer pH 7.4 (DMEM containing 20 raM Hepes and 1 mg/ ml gelatin), and incubated with the desired concentrations of iodinated VAS-VEGF in a final volume of 500 fj\. Nonspecific binding was determined in the presence of a large excess of unlabeled ligand (500 ng). Both total and nonspecific binding were determined in duplicate. The dishes were incubated at 4°C on an oscillating platform rotating at 1 cyc/sec for 3 hours. At the end of incubation, the medium was withdrawn, and cells were washed five times with cold binding buffer and solubilized by the addition of 0.5 M NaOH. The amount of radioactivity bound to the cells was counted in a gamma counter. At saturating concentrations, nonspecific binding was less than 20%. Receptor affinity and the number of binding sites per cell were determined by Scatchard's analysis. 17 The bioactivity of VAS-VEGF in BREC and FBAE-CM was determined by a radioreceptor assay as described previously. 16 Briefly, subconfluent FBAEs were incubated at 4°C for 3 hours with 0.8 ng/ml of iodinated VAS-VEGF 165 and 10 /zl of each fraction of conditioned medium eluted from the affinity column. VAS-VEGF-like activity in the different fractions was determined by comparison with a standard curve generated for recombinant growth factor.
Cell Proliferation and Migration Assays
Low-density BRECs (10 4 cells per 12-well cluster plates) were seeded in gelatin-coated dishes containing DMEM supplemented with 10% calf serum. After 24 hours, the medium was changed and increasing concentrations of growth factors or BREC-conditioned medium (BREC-CM) were added at day 1 and day 3. After 5 days in culture, the culture dishes were trypsinized and cell density was determined using a Coulter counter, dta are the means ± SE of three different experiments.
Confluent monolayers of BREC in gelatin-coated, six-well cluster plates were growth arrested by exposure to serum-free DMEM for 12 hours and then wounded with a rubber policeman. The dishes were washed with medium to remove scraped cells that might release factors influencing migration. Each well was immediately photographed at 100X magnification. Triplicate dishes were then incubated for 16 hours in DMEM in the presence of VAS-VEGF, bFGF, BREC-CM, or 10% calf serum. A second photograph of each well was taken after incubation at the same magnification. Migration was then quantified by superimposing the first and second photographs of each wound and counting the cells that had migrated from the initial wound edge, dta are the means ± SE from four experiments.
For the autocrine experiment, affinity-purified anti-VAS-VEGF antibody (5 //g/ml) was added immediately after wounding with or without VAS-VEGF (1 ng/ml) or BREC-CM (2 //I/ml).
Comparisons with control cells were performed using the Mann-Whitney test. A probability value of less than 0.05 was accepted as statistically significant.
Reverse Transcription Polymerase Chain Reaction
Total RNAs were extracted from cells by the guanidine thiocyanate method (RNAzol, Biotecx, Inc./Bioprobe Systems, France). cDNA was synthesized from a total extraction product using random primers and a cDNA synthesis kit (Super Script Preamplification System, VAS-VEGF and Retinal Endothelial Cells 3395 BRL; Life Technologies, Eragny, France). Sense and antisense primers (3' anti-sense: TCACCGCCTTGGC-TTGTC; 5' sense: AACCATGAACTTTCTGCTGTC) were chosen to amplify fragments corresponding to the different forms of VAS-VEGF. They flanked the VAS-VEGF sequence from base 65 to base 768 as numbered by Houck et al. 7 This sequence contains one Ncol restriction site at position 151. Polymerase chain reaction (PCR) amplification was performed using 1 /il of the reverse transcription product, 50 pmoles of each primer, 250 fiM of each dNTP, and 2.5 U of Taq polymerase in a total volume of 50 //I. The cDNA was amplified by 30 cycles (94°C for 1 minute; 57°C for 1 minute; 72°C for 1.5 minutes). Onefifth the volume of PCR reaction was subject to electrophoresis on a 1.5% agarose gel, and fragments were detected by staining the gel with ethidium bromide. Standard size markers were 1 kb BRL. Positive controls were performed with plasmids containing a cDNA VAS-VEGF sequence. Negative controls were carried out without reverse transcription sample. To confirm the specificity of amplification, restriction enzyme analysis was performed by Ncol.
Purification of the Conditioned Media
One liter of BREC or FBAE-CM was precipitated by 500 g ammonium sulphate, dialysed against 50 mM Tris pH 7.2 containing 50 mM NaCl and applied to a heparin-sepharose affinity column (0.2 to 0.3 cm). Bound proteins were eluted by a stepwise gradient of NaCl (0.3, 0.8, and 2.0 M NaCl). Fractions of 150 //I were collected. All the fractions were then assayed for their VAS-VEGF activity by a radioreceptor assay. 16 The fractions containing the peak of activity were pooled and tested for their mitogenic activity on BRECs, their VAS-VEGF content by a radioreceptor assay.
Their molecular weight was further characterized by Western blot analysis. The samples were subject to electrophoresis through a 15% SDS-PAGE under reducing conditions {(3 mercaptoethanol 0.1 M). The proteins electrotransferred onto a nitrocellulose membrane were incubated with chicken anti-VAS-VEGF antibody at a 1 /xg/ml dilution. Horseradish peroxydase-labeled antichicken antibodies at a 1:15,000 dilution were used to visualize bound antibody using the enhanced chemiluminescence Western blotting detection system.
RESULTS
VAS-VEGF Binds to BRECs on Two Binding Sites
Binding sites for VAS-VEGF were characterized in experiments studying the concentration dependence of the binding of 1 ' 8 The abscissae interceptions indicated the presence of 600 and 9600 sites per cell, respectively (Fig. 1) .
VAS-VEGF Promotes the Proliferation and the Migration of BRECs
BRECs seeded at low density proliferated slowly when exposed to DMEM supplemented with calf serum. The addition of increasing concentrations of VAS-VEGF improved the growth rate in a dose-dependent manner. The concentration of optimal cell proliferation was about 2 ng/ml with a half-maximal stimulation (ED 50) achieved with 0.3 ng/ml of VAS-VEGF. At the optimal concentration, the final cell density was twofold higher than control cells (Fig. 2A) .
When comparing mitogenic effects of VAS-VEGF to that of bFGF (2 ng/ml), it appeared that VAS-VEGF is a less potent mitogen than bFGF for BRECs. The final cell density was fivefold higher when adding bFGF at its optimal concentration (2 ng/ml) (Fig. 2B) . Furthermore, adding bFGF and VEGF simultaneously did not result in an additional mitogenic effect (data not shown).
In another set of experiments, it was shown that BRECs could migrate upon exposure to VAS-VEGF (Fig. 3) . Control cells incubated without any growth 100 VEGF (ng/ml) 10 -
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O m FIGURE 2. Mitogenic effect of VAS-VEGF on BREC proliferation, dta are the mean ± SE of triplicate experiments. (A) Low-density BRECs were exposed to DMEM supplemented with 10% calf serum. Increasing concentrations of VAS-VEGF were added at day 1 and day 3. After 5 days, the dishes were trypsinized and the cells were counted. (B) Comparison with the mitogenic effect of bFGF. Final cell densities of BRECs exposed to VAS-VEGF or bFGF at optimal concentrations (2 ng/ml) were indicated. Control cells were exposed to 10% calf serum. factors migrated little (Fig. 3A: photographs 1 and  2 ). The addition of VAS-VEGF stimulated the BRECs migration in a dose-dependent manner. The optimal effect was achieved with a concentration of 1 ng/ml (Fig. 3A: photographs 3 and 4) . At a dose of 1 ng/ ml, the number of cells that migrated toward the wound was twofold higher than that of control cells (P< .01) (Fig. 3B) . Adding bFGF (2 ng/ml) increased BRECs migration without a statistically significant difference when compared with VEGF (Fig. 3B) .
VEGF Is Continuously Synthesized by BRECs
The RT-PCR analysis of the expression of VAS-VEGF mRNA in BRECs is shown in Figure 4 . Figures 4A and   4B represent the two BREC clones subject to RT-PCR analysis. Two bands of 441 and 573 bp were detected, corresponding to VAS-VEGF 121 and 165, respectively (Fig. 4C) . Cleavage by Ncol yielded 86-bp shorter fragments, namely 355 and 487 bp, confirming the specificity of the amplification (Fig. 4D) .
To ascertain if these messengers were actively translated, BREC-CM was loaded on a heparin affinity column, and the bound material was subsequently eluted by a stepwise NaCl gradient. The different fractions were then assayed for their VAS-VEGF content by a radioreceptor assay (Fig. 5A) . Two peaks of bioac- tivity were eluted at 0.3 and 0.8 M NaCl, chromatographic behavior highly reminiscent of VAS-VEGF. 1 The fractions were then pooled and further quantified. It appeared (Fig. 5B ) that the 0.3 and 0.8 M NaCl pooled fractions contained 2 and 2.2 ng/fi\ of VAS-VEGF-like bioactivity, respectively, corresponding to 5 ng/10 6 cells per 48 hours. No bioactivity could be detected in FBAE-derived conditioned medium. For further characterization, bioactive fractions were analyzed by Western blot. Two bands with apparent molecular masses of 18 and 23 kd were observed under reducing conditions, whereas no band was detected in FBAE-purified conditioned medium (Fig. 6 ).
Autocrine Action of VAS-VEGF on BRECs
Purified BREC-CM increased BREC migration (Fig.  7) . The optimal effect was achieved with 2 //I/ml of BREC-CM. At this concentration, the number of cells that had migrated was 1.6-fold higher than control cells (P < .05). This effect of the BREC-conditioned medium was partially neutralized by anti-VAS-VEGF antibodies. Similar results were obtained in proliferation assays with a less potent effect (final cell density 1.3-fold higher) (data not shown), confirming the autocrine action of VAS-VEGF on BRECs.
DISCUSSION
In this study, we prove for the first time to our knowledge that VAS-VEGF is an autocrine growth factor for BRECs. BRECs have the ability to bind VAS-VEGF on high-affinity binding sites. This binding is saturable and maximal at a concentration of 4 ng/ml. Scatchard's analysis revealed the presence of two types of binding sites with apparent dissociation constants of 2 and 56 pM and corresponding to 600 and 9600 sites per cell, respectively. These results are similar to those previously reported for bovine endothelial cells de- rived from microvessels from the adrenal gland 16 or brain. 18 Although the dissociation constants are similar, the number of binding sites is lower than in aortic arch-derived endothelial cells.
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VAS-VEGF induces the proliferation and migration of BRECs, two crucial steps of retinal angiogenesis. The mitogenic effect of VAS-VEGF on BRECs is comparable to the response obtained with other endothelial cells 12 and shows that only a part of the binding sites must be occupied to promote the biologic response. As reported for other endothelial cells, the effect of VAS-VEGF on cell migration is as potent as that of bFGF.
These results provide evidence that BRECs can release VAS-VEGF into their culture medium by the use of several criteria: mRNA expression for VAS/ VEGF 121 and 165 as detected by RT-PCR analysis; chromatographic behavior on heparin affinity columns identical to that of VAS-VEGF; presence of immunoreactive VAS-VEGF corresponding to molecular weight of 23,000 and 18,000 d as judged by Western blot analysis. Although we did not find any VAS-VEGF-like bioactivity in the conditioned medium of endothelial cells derived from bovine aortic arch (described herein) or adrenal cortex, 9 it seems that only endothelial cells cultured from the retina or brain 20 might express VAS-VEGF. This could reflect specific roles played by VAS-VEGF in neural tissues, such as its contribution to the regulation of capillary permeability.
In addition, the neutralization of the bioactivity of the BREC-conditioned medium by anti-VAS-VEGF antibodies suggests that VAS-VEGF acts through an autocrine regulation on these cells. This regulation, demonstrated for the first time, could be effective because BRECs synthesize VAS-VEGF at a concentration (>1 ng/ml) compatible with a biologic effect. We previously reported that BRECs also release bFGF into their medium. 14 A VAS-VEGF autocrine action on retinal endothelial cells might act in concert with that of bFGF to trigger differentiation, as has been reported for other microvascular endothelial cells. 21 Whether or not this synergy is due to a positive stimulation of the expression of VAS-VEGF by bFGF as it occurs in smooth muscle cells 22 remains to be investigated. Furthermore, in addition to its autocrine activity on BRECs, VAS-VEGF acts on these cells through a paracrine pathway because it is also released in a bioactive form by retinal pericytes. 23 Taking into account the fact that endothelial cells are maintained in a nonproliferative state, we can advance the following hypothesis. VAS-VEGF activates the transcription of plasminogen activator on microvessel-derived endothelial cells 24 and in turn activates the latent TGF f5 released by pericytes, 25 which could counterbalance the action of VAS-VEGF. Furthermore, in pathologic conditions such as hypoxia, VAS-VEGF might be overexpressed by BRECs, so it could induce an imbalance between angiogenic and inhibitory molecules and lead to retinal neovascularization. Such increased synthesis of VAS-VEGF was in fact recently described in the necrotic area of neural tumors. 26 The elucidation of growth factors that can regulate angiogenesis is of considerable relevance to pathologic processes. However, the precise nature and the origin of these angiogenic mediators remain unclear. VAS-VEGF appears to be a suitable candidate because it is secreted by endothelial cells themselves, and, at least in vitro, it can control the steps (proteases activation, migration, proliferation, differentiation) of 3399 the cascade leading to the angiogenic response. Furthermore, these in vitro conclusions should be considered in the light of our in vivo results on the constant expression of VAS-VEGF transcripts in diabetic neovascular membranes and the increase of VAS-VEGF levels in the vitreous of patients with diabetes (submitted for publication). Nevertheless, further studies are required to specify fully the actual role of VAS-VEGF in retinal physiology and in pathologic processes such as proliferative diabetic retinopathy.
